Wednesday, July 8, 2026

Patent directory · USPTO A61K / A61P

Patents matching “Theravance Biopharma R&D IP, LLC”

252 pharma patents match "Theravance Biopharma R&D IP, LLC" in our USPTO index (A61K/A61P) — applicant, grant date, expiration, and drug links.

Matches 252
Index total 30,257
Page 1 / 11

Quick answer

This filtered view shows 252 pharmaceutical patents matching "Theravance Biopharma R&D IP, LLC" in our USPTO PatentsView index (CPC A61K/A61P). Search matches patent number, title, applicant, and CPC classification codes.

Patent results

252 results for “Theravance Biopharma R&D IP, LLC” · 30,257 patents in full index Clear search

  1. US 12384761

    Imidazolo indazole compounds as JAK inhibitors

    Theravance Biopharma R&D IP, LLC · Granted Aug 12, 2025 · Expires Aug 7, 2045

    granted
  2. US 12358931

    3-((1R,3s,5S)-3-((7-((5-methyl-1H-pyrazol-3-yl)amino)-1,6-naphthyridin-5-yl)amino)-8-azabicyclo[3.2.1]octan-8-yl) propanenitrile as a JAK kinase inhibitor

    Theravance Biopharma R&D IP, LLC · Granted Jul 15, 2025 · Expires Jul 10, 2045

    granted
  3. US 12351561

    Crystalline (2S,4R)-5-(5'-chloro-2'-fluoro-[1,1'-biphenyl]-4-yl)-2-(ethoxymethyl)-4-(3-hydroxyisoxazole-5-carboxamido)-2-methylpentanoic acid and uses thereof

    Theravance Biopharma R&D IP, LLC · Granted Jul 8, 2025 · Expires Jul 3, 2045

    granted
  4. US 12285417

    Methods for treating chronic obstructive pulmonary disease

    Theravance Biopharma R&D IP, LLC · Granted Apr 29, 2025 · Expires Apr 24, 2045

    granted
  5. US 12258316

    Biphenyl compounds useful as muscarinic receptor antagonists

    Theravance Biopharma R&D IP, LLC · Granted Mar 25, 2025 · Expires Mar 20, 2045

    granted
  6. US 12239638

    Crystalline form of a 4-[2-(2-fluorophenoxymethyl)phenyl]piperidine compound

    Theravance Biopharma R&D IP, LLC · Granted Mar 4, 2025 · Expires Feb 27, 2045

    granted
  7. US 12172994

    Pyrimidine compound as JAK kinase inhibitor

    Theravance Biopharma R&D IP, LLC · Granted Dec 24, 2024 · Expires Dec 19, 2044

    granted
  8. US 12122773

    Crystalline hydrate of a JAK inhibitor compound

    Theravance Biopharma R&D IP, LLC · Granted Oct 22, 2024 · Expires Oct 17, 2044

    granted
  9. US 12048692

    Methods for treating chronic obstructive pulmonary disease

    Theravance Biopharma R&D IP, LLC · Granted Jul 30, 2024 · Expires Jul 25, 2044

    granted
  10. US 12016835

    Neprilysin inhibitors

    Theravance Biopharma R&D IP, LLC · Granted Jun 25, 2024 · Expires Jun 20, 2044

    granted
  11. US 11919888

    Neprilysin inhibitors

    Theravance Biopharma R&D IP, LLC · Granted Mar 5, 2024 · Expires Feb 29, 2044

    granted
  12. US 11878977

    JAK inhibitors containing a 4-membered heterocyclic amide

    Theravance Biopharma R&D IP, LLC · Granted Jan 23, 2024 · Expires Jan 18, 2044

    granted
  13. US 11858898

    Crystalline freebase forms of a biphenyl compound

    Theravance Biopharma R&D IP, LLC · Granted Jan 2, 2024 · Expires Dec 28, 2043

    granted
  14. US 11851443

    Neprilysin inhibitors

    Theravance Biopharma R&D IP, LLC · Granted Dec 26, 2023 · Expires Dec 21, 2043

    granted
  15. US 11845747

    Ester and carbonate pyrimidine compounds as JAK kinase inhibitors

    Theravance Biopharma R&D IP, LLC · Granted Dec 19, 2023 · Expires Dec 14, 2043

    granted
  16. US 11814377

    Pyrimidine compound as JAK kinase inhibitor

    Theravance Biopharma R&D IP, LLC · Granted Nov 14, 2023 · Expires Nov 9, 2043

    granted
  17. US 11795180

    Formulation of a pan-JAK inhibitor

    Theravance Biopharma R&D IP, LLC · Granted Oct 24, 2023 · Expires Oct 19, 2043

    granted
  18. US 11786517

    Methods of treatment using a JAK inhibitor compound

    Theravance Biopharma R&D IP, LLC · Granted Oct 17, 2023 · Expires Oct 12, 2043

    granted
  19. US 11780852

    Methods for treating Crohn's disease using 3-((1R,3s,5S)-3-((7-((5-methyl-1H-pyrazol-3-yl)amino)-1,6-naphthyridin-5-yl)amino)-8-azabicyclo[3.2.1]octan-8-yl)propanenitrile

    Theravance Biopharma R&D IP, LLC · Granted Oct 10, 2023 · Expires Oct 5, 2043

    granted
  20. US 11730720

    ALK5 inhibitors

    Theravance Biopharma R&D IP, LLC · Granted Aug 22, 2023 · Expires Aug 17, 2043

    granted
  21. US 11723900

    4-[2-(2-fluorophenoxymethyl)phenyl]piperidine compounds

    Theravance Biopharma R&D IP, LLC · Granted Aug 15, 2023 · Expires Aug 10, 2043

    granted
  22. US 11718591

    Crystalline (2S,4R)-5-(5′-chloro-2′-fluoro-[1,1′-biphenyl]-4-yl)-2-(ethoxymethyl)-4-(3-hydroxyisoxazole-5-carboxamido)-2- methylpentanoic acid and uses thereof

    Theravance Biopharma R&D IP, LLC · Granted Aug 8, 2023 · Expires Aug 3, 2043

    granted
  23. US 11718616

    JAK kinase inhibitor compounds for treatment of respiratory disease

    Theravance Biopharma R&D IP, LLC · Granted Aug 8, 2023 · Expires Aug 3, 2043

    granted
  24. US 11713315

    5 to 7 membered heterocyclic amides as JAK inhibitors

    Theravance Biopharma R&D IP, LLC · Granted Aug 1, 2023 · Expires Jul 27, 2043

    granted